Edition:
India

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.70USD
19 Jan 2018
Change (% chg)

$0.02 (+1.19%)
Prev Close
$1.68
Open
$1.66
Day's High
$1.70
Day's Low
$1.66
Volume
5,606
Avg. Vol
87,257
52-wk High
$10.90
52-wk Low
$1.53

Select another date:

Tue, Jan 9 2018

BRIEF-Cyclacel Pharma Projects Cash Resources To Fund Currently Planned Programs Through End Of 2019

* CYCLACEL PHARMACEUTICALS INC - CO PROJECTS CASH RESOURCES TO FUND CURRENTLY PLANNED PROGRAMS THROUGH END OF 2019 Source text for Eikon: Further company coverage:

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia​

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

BRIEF-Cyclacel Pharmaceuticals Q2 loss per share $0.50

* Cyclacel Pharmaceuticals reports second quarter 2017 financial results

BRIEF-Intra-Cellular Therapies reports Q2 loss per share $0.41

* Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update

BRIEF-Cyclacel announces selection of recommended phase 2 dose for CYC065

* Cyclacel announces selection of recommended phase 2 dose for CYC065 and evidence of durable target engagement and MCL-1 biomarker suppression Source text for Eikon: Further company coverage:

Select another date: